Pluri Inc. (PLUR), a clinical-stage biotechnology company focused on developing novel cell therapy products, is currently trading at $3.35, marking a 1.33% decline in recent trading sessions. This analysis reviews key technical levels, prevailing market context, and potential price scenarios for the stock, with no investment recommendations included. Key levels to monitor in upcoming sessions include a near-term support floor at $3.18 and a near-term resistance ceiling at $3.52, both of which ha
PLUR Stock Analysis: Pluri Inc. drops 1.33% to $3.35, key support levels assessed
PLUR - Stock Analysis
3704 Comments
1843 Likes
1
Lennox
Regular Reader
2 hours ago
Can we start a group for this?
π 54
Reply
2
Albert
Engaged Reader
5 hours ago
Missed the timingβ¦ sigh. π
π 133
Reply
3
Carsten
Daily Reader
1 day ago
Indices continue to test resistance and support zones, providing key levels for trading decisions.
π 96
Reply
4
Zenniyah
Engaged Reader
1 day ago
Effort like this motivates others instantly.
π 281
Reply
5
Hayz
Returning User
2 days ago
US stock customer concentration analysis and revenue diversification assessment for business risk evaluation. We identify companies with too much dependency on single customers or concentrated revenue sources.
π 271
Reply
Disclaimer: Not investment advice. For informational purposes only. Past performance does not guarantee future results. Trading involves substantial risk of loss.